GEC NEWS WIRESoftware AG’s new research programme supported by the Innovative Medicines Initiative (IMI) developed new ways of monitoring major depressive disorder, epilepsy, and multiple sclerosis using wearable devices and smartphone technology.
The RADAR-CNS (Remote assessment of disease and relapse – Central Nervous System) programme aims to improve patients’ quality of life, and potentially to change how these and other chronic disorders are treated.
Continuous remote assessment using smartphones and wearable devices provides a complete picture of a patient’s condition at a level of detail which was previously unachievable. Moreover, it could potentially allow treatment to begin before a patient’s health deteriorates, preventing the patient relapsing or becoming more ill before they seek treatment.
Software AG will provide key elements of its Digital Business Platform, including Apama Big Data Streaming Analytics and Terracotta In-Memory Data Fabric.
Dr. Giles Nelson, Software AG’s Senior Vice President of Product Management said, “The Digital Business Platform will enable researchers to access unprecedented amounts of data from wearable smart devices in real-time for deep insights into brain disorders, ‘personalized analytics’, and early warnings of aberrant behavior.”
Wherever possible, RADAR-CNS will use inexpensive and widely available technology, so that the end results can be made available to as many patients as possible. The research will also be developed in a way that allows the results to be transferred to other diseases, potentially allowing the benefits of remote measurement technologies to become pervasive in medicine, and transforming the way we think about prevention and cure.
